LEHI, Utah, July 14, 2026
CancerVax announced the successful development and in vitro validation of a novel Polyepitope Smart mRNA designed to harness pre-existing T-cell immunity by making cancer cells appear as multiple common viral infections. The preclinical platform is engineered to selectively activate within cancer cells, prompting them to express viral proteins that trigger existing immune memory and direct immune attacks against tumors. The company reported that its latest Version 2 Polyepitope Smart mRNA design achieved an estimated 99.5% global population coverage, representing a significant milestone in the development of its universal cancer immunotherapy platform.
Polyepitope Smart mRNA Expands Immune Recognition Strategy
CancerVax’s Smart mRNA technology is designed to activate only inside cancer cells, where it instructs them to produce multiple viral epitopes associated with highly prevalent infections, including measles, influenza, cytomegalovirus (CMV), and others. By presenting these familiar viral markers, the platform aims to recruit pre-existing memory T cells that already recognize these pathogens, enabling the immune system to identify and eliminate cancer cells without targeting healthy tissue. The company stated that recent in vitro studies successfully validated this multi-epitope strategy and demonstrated its potential to broaden immune activation across diverse patient populations.
AI-Assisted Design Achieves Broad Global Population Coverage
Using large-scale immune epitope datasets together with AI-assisted computational analysis, CancerVax identified combinations of viral epitopes that maximize immune recognition across different human leukocyte antigen (HLA) profiles. The initial Version 1 Polyepitope Smart mRNA was estimated to provide 96.26% global population coverage, while an expanded Version 2 design increased estimated coverage to 99.50%, according to analysis using the Immune Epitope Database (IEDB) population coverage algorithm. The company believes this broad coverage could significantly improve the likelihood that patients possess pre-existing T-cell immunity capable of recognizing at least one encoded viral epitope.
Advertisement
Preclinical Platform Advances Toward Universal Cancer Immunotherapy
CancerVax is developing its Smart mRNA technology as a customizable, injectable universal cancer treatment platform intended for multiple cancer types. The company believes leveraging naturally acquired immune memory offers a differentiated approach to cancer immunotherapy by detecting, marking, and selectively eliminating malignant cells while sparing healthy tissue. Following successful design and laboratory validation of its Polyepitope Smart mRNA, CancerVax plans to continue advancing the platform through additional preclinical development toward future clinical evaluation.
Source: CancerVax, press release
